Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06372457 · ClinicalTrials.gov registry record
COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
A clinical trial of Hypertrophic Cardiomyopathy (HCM), sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT06372457 is a study of Hypertrophic Cardiomyopathy (HCM) that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06372457, a study of Hypertrophic Cardiomyopathy (HCM), is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.
Conditions Studied
Interventions
- DRUG Mavacamten
- DRUG Approved Hypertrophic Cardiomyopathy drug treatments
Study Locations (1)
North Carolina
- IQVIA - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-12-01 |
| Est. Completion | 2025-06-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06372457
The ClinicalTrials.gov registry entry for NCT06372457 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertrophic Cardiomyopathy (HCM) appearing as the primary indexed condition, and to 2 interventions - of which Mavacamten is the first listed.
NCT06372457 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06372457 about?
NCT06372457 is a clinical study titled "COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)". COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.
What is the current status of trial NCT06372457?
This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2023-12-01. Estimated completion is 2025-06-15.
What conditions does trial NCT06372457 study?
This clinical trial studies the following conditions: Hypertrophic Cardiomyopathy (HCM).
What interventions are being tested in trial NCT06372457?
The interventions under investigation include: Mavacamten (DRUG), Approved Hypertrophic Cardiomyopathy drug treatments (DRUG).
Who is sponsoring clinical trial NCT06372457?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06372457 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertrophic Cardiomyopathy (HCM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.